Mitsubishi UFJ Trust & Banking Corp Reduces Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mitsubishi UFJ Trust & Banking Corp lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 116,686 shares of the biopharmaceutical company’s stock after selling 3,646 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.09% of Alnylam Pharmaceuticals worth $27,457,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Regeneron Pharmaceuticals Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $1,045,822,000. Raymond James Financial Inc. purchased a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $65,295,000. Jennison Associates LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $61,160,000. Proficio Capital Partners LLC lifted its position in shares of Alnylam Pharmaceuticals by 25,929.6% during the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock worth $45,570,000 after acquiring an additional 192,916 shares in the last quarter. Finally, Strategic Financial Concepts LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $41,529,000. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ALNY shares. Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a report on Friday, March 21st. Needham & Company LLC reissued a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Royal Bank of Canada boosted their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research note on Friday, March 21st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $280.00 to $328.00 in a research note on Monday. Finally, Chardan Capital restated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $312.30.

Alnylam Pharmaceuticals Stock Down 4.2 %

ALNY opened at $269.21 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The business’s 50-day moving average price is $258.98 and its 200-day moving average price is $260.32. The company has a market cap of $34.85 billion, a P/E ratio of -124.06 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares of the company’s stock, valued at $8,366,003.62. This represents a 2.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the sale, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock valued at $19,958,097 in the last quarter. Company insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.